Dr. Goede on the Results from the Phase III CLL11 Trial
Valentin Goede, MD
Published Online: Wednesday, June 19, 2013
Valentin Goede, MD, Department I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, University of Cologne, Germany, discusses the findings of the phase III CLL11 trial.
The CLL11 trial evaluated obinutuzumab (GA101) plus chlorambucil or rituximab plus chlorambucil versus chlorambucil alone in patients with chronic lymphocytic leukemia (CLL) and comorbidities.
Researchers found that the combination of obinutuzumab and chlorambucil prolonged progression-free survival significantly compared with chlorambucil alone. The most important piece of this finding, Goede notes, is the hazard ratio (0.14), which signifies an 86% reduction in risk of progressing with CLL in these patients. The trial also found that the hazard ratio for rituximab and chlorambucil compared with chlorambucil alone was 0.32.
Goede says that obinutuzumab and rituximab cannot be compared head-to-head with this data alone.
Ruxolitinib, a JAK1/2 inhibitor, is the first treatment to demonstrate efficacy in a phase III trial for patients with polycythemia vera (PV), a chronic, incurable blood cancer with limited treatment options